Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZF2001 protein subunit vaccine as heterologous booster dose COVID-19 vaccine (immunobridging study)
TCTR20220318001Phase 3Not yet recruiting
- Sponsor
- Chulabhorn Royal Academy
- Start
- Apr 2022
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ZF2001 in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Royal Academy. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
ZF2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220318001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220318001.